Bacillus Calmette-Guérin contact immunotherapy of local and metastatic deposits of rat tumors.
Adjuvant contact therapy with BCG can be used to control tumor deposits at local subcutaneous sites and at other sites, particularly pulmonary metastases and pleural tumor growths. This treatment method is generally quantitatively more effective than general immunostimulation, or active immunotherapy that employs vaccines of adjuvant and tumor cells. Furthermore, this treatment is effective in hosts that lack full immunocompetence, making it still feasible in immunosuppressed patients. The current evidence indicates that local activation of host macrophages is probably the essential effector mechanism of adjuvant contact therapy.
D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy; D008297:Male; D008748:Methylcholanthrene; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000628:therapy*; D010997:Pleural Neoplasms / Q000276:immunology / Q000628:therapy; D051381:Rats; D011919:Rats, Inbred Strains; D012513:Sarcoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy
D001500:BCG Vaccine; D008748:Methylcholanthrene